COMMUNIQUÉS West-GlobeNewswire

Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Transactions in connection with share buy-back program
13/10/2026
Company announcement no. 39 - 26 13 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China
13/10/2026
BEIJING, Oct. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
Leo International Precision Health AG implements capital increase from company reserves
13/10/2026
Planegg / Martinsried, October 13, 2026 – Leo International Precision Health AG (“LIPH”, ticker symbol: LEOW), a holding company building a global integrated AI-driven healthcare ecosystem, is implementing the technical [...]
Zelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress Update
13/10/2026
Oslo, 13 October 2026 – Zelluna (OSE: ZLNA), a clinical-stage biotechnology Company pioneering allogeneic, off-the-shelf T-cell receptor-based natural killer (TCR-NK) cell therapies for solid cancers, will publish its [...]
Teva to Host R&D Day on Wednesday, November 11 in New York City
12/10/2026
TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva’s [...]
NexLife Announces October 2026 GLP-1 Price Index on Online Prices of Compounded Tirzepatide and Semaglutide
13/10/2026
WILMINGTON, Del., Oct. 12, 2026 (GLOBE NEWSWIRE) -- NexLife announces a new report, the October 2026 NexLife GLP-1 Price Index, on the monthly prices of compounded tirzepatide and compounded semaglutide at online [...]
Diazyme Laboratories, Inc. Acquires Alfa Wassermann Diagnostic Technologies LLC.
12/10/2026
POWAY, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Diazyme Laboratories, Inc. announced today that it has acquired the business of Alfa Wassermann Diagnostic Technologies LLC. (AWDT) from CARR Biosystems. AWDT is an FDA [...]
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
12/10/2026
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE [...]
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
12/10/2026
– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – – Axatilimab continues to [...]
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
12/10/2026
AUDUBON, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2026 after [...]
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
12/10/2026
NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative [...]
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
12/10/2026
New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near term Three patent applications are pending, including two method [...]
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
12/10/2026
Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. [...]
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
12/10/2026
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting for [...]
ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
12/10/2026
PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf [...]

Pages